Free publications from VelaLabs experts I VelaLabs

Surface Plasmon Resonance for Determination of Potency.

Gaderer, S. (2022). Pharm. Ind. 84, Nr. 7, 909 – 917 (2022) © ECV • Editio Cantor Verlag, Aulendorf (Germany).

READ FULL ARTICLE HERE

Download Surface Plasmon Resonance for Determination of Potency

Insight into biosimilars: Short description, analytical assessment and market.

Zimmermann, K, Fido, M, and Roucka, M. (2020). Medical Research Archives 8: issue 3.

READ FULL ARTICLE HERE

Download Biosimilar Review

Glycosylation pattern of biotechnologically produced proteins – lectin array technology as a versatile tool for screening?

Zimmermann, K, Fido, M, and Roucka, M. (2018). Medical Research Archives 6: issue 3.

READ FULL ARTICLE HERE

Download Lectin Array Review

Application of lectin array technology for biobetter characterization: its correlation with FcγRIII binding and ADCC. Microarrays.

Roucka, M, Zimmermann, K, Fido, M, and Nechansky, A. (2017). 6:1.

READ FULL ARTICLE HERE

Download Lectin Array Application

Introduction of the hybcell-based compact sequencing technology and comparison to state-of-the-art methodologies for KRAS mutation detection.

Zopf, A, Raim, R, Danzer, M, Niklas, N, Spilka, R, Pröll, J, Gabriel, C, Nechansky, A, and Roucka, M. (2015). Biotechniques. 58:126 – 134.

READ FULL ARTICLE HERE

Download hybcell-based compact sequencing technology

Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y‑specific monoclonal antibody MB314.

Kircheis, R, Halanek, N, Koller, I, Jost, W, Schuster, M, Gorr, G, Hajszan, K, and Nechansky, A. (2012). MAbs. 4:532 – 541.

READ FULL ARTICLE HERE

Download Correlation ADCC Cytokines

Immunogenicity of therapeutics: a matter of efficacy and safety.

Nechansky, A, and Kircheis R. (2010). Drug Discov. 5:1 – 13.

READ ABSTRACT HERE

Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.

Nechansky, A. (2010). HAHA – nothing to laugh about. J. Pharm. Biomed. Anal. 51:252 – 254.

READ ABSTRACT HERE

For reprints please contact us HERE

Name	Google Analytics, Google Tag Manager
Provider	Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Purpose	Cookie by Google used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy	https://policies.google.com/privacy
Cookie Name	_ga, _gat, _gid
Cookie Expiry	2 years

Name	LinkedIn Corporation
Provider	LinkedIn Corporation, 605 W Maude Ave, Sunnyvale, CA 94085, USA
Purpose	Cookie by LinkedIn used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy	https://www.linkedin.com/legal/privacy-policy
Cookie Name
Cookie Expiry	2 years

Name	LiveChat
Provider	LiveChat Software S.A., ul. Zwycięska 47, 53-033 Wroclaw, Poland
Purpose	Communication with clients via online chat using the API of the chat service LiveChat.
Privacy Policy	https://www.livechat.com/legal/privacy-policy/
Cookie Name	__lc_cid, __lc_cst
Cookie Expiry	2 years

Name	Cookie Consent
Provider	Owner of this website, Imprint
Purpose	Saves the visitors preferences selected in the cookie banner.
Cookie Name	ws_cookie_consent
Cookie Expiry	1 year

Publications

Publications from VelaLabs experts

Insight into biosimilars: Short description, analytical assessment and market.

Glycosylation pattern of biotechnologically produced proteins – lectin array technology as a versatile tool for screening?

Application of lectin array technology for biobetter characterization: its correlation with FcγRIII binding and ADCC. Microarrays.

Introduction of the hybcell-based compact sequencing technology and comparison to state-of-the-art methodologies for KRAS mutation detection.

Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y‑specific monoclonal antibody MB314.

Immunogenicity of therapeutics: a matter of efficacy and safety.

Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.

Insight into biosim­i­lars: Short descrip­tion, analyt­ical assess­ment and market.

Glyco­sy­la­tion pattern of biotech­no­log­i­cally produced proteins – lectin array tech­nology as a versa­tile tool for screening?

Appli­ca­tion of lectin array tech­nology for biobetter char­ac­ter­i­za­tion: its corre­la­tion with FcγRIII binding and ADCC. Microarrays.

Intro­duc­tion of the hybcell-based compact sequencing tech­nology and compar­ison to state-of-the-art method­olo­gies for KRAS muta­tion detection.

Corre­la­tion of ADCC activity with cytokine release induced by the stably expressed, glyco-engi­neered human­ized Lewis Y‑specific mono­clonal anti­body MB314.

Immuno­genicity of ther­a­peu­tics: a matter of effi­cacy and safety.

Measuring the immuno­genicity (human anti-human anti­body response) induced by human­ized mono­clonal anti­bodies applying ELISA and SPR technology.

Insight into biosimilars: Short description, analytical assessment and market.

Glycosylation pattern of biotechnologically produced proteins – lectin array technology as a versatile tool for screening?

Application of lectin array technology for biobetter characterization: its correlation with FcγRIII binding and ADCC. Microarrays.

Introduction of the hybcell-based compact sequencing technology and comparison to state-of-the-art methodologies for KRAS mutation detection.

Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y‑specific monoclonal antibody MB314.

Immunogenicity of therapeutics: a matter of efficacy and safety.

Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.